IC
AGIO icon

Ikarian Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Ikarian Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-115,489
Closed -$3.14M – 164
2025
Q4 		$3.14M Sell
115,489
-11,490
-9% -$403K 0.25% 82
2025
Q3 		$5.1M Buy
+126,979
New +$4.78M 0.51% 47

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Ikarian Capital's AGIO Position: Q1 2026 in Review

Ikarian Capital sold out of Agios Pharmaceuticals (AGIO) in Q1 2026, closing a stake of 115,489 shares — an estimated $3.14M sold.

Ikarian Capital first reported a position in AGIO in Q3 2025 and held it in 2 quarters. The position peaked at $5.1M in Q3 2025. 234 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Ikarian Capital reported no remaining Agios Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Ikarian Capital sold 115,489 Agios Pharmaceuticals shares in Q1 2026, an estimated $3.14M.
  • Ikarian Capital first reported a position in Agios Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Ikarian Capital's Agios Pharmaceuticals position peaked at $5.1M in Q3 2025.
  • 234 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.